Addex Therapeutics regains global rights to Indivior’s GABAB PAM assets
AI Summary- Addex Therapeutics regained global rights to GABAB PAM assets from Indivior UK Limited.
- Addex’s substance-use-disorder candidate completed IND-enabling studies, while its chronic-cough program is ready to begin them.
- The rights returned after Indivior rationalized research activities and announced its parent company’s planned merger with Supernus Pharmaceuticals.